Neko Health Raises $700M Series C Ahead of US Launch

Neko Health, the preventive-healthcare company co-founded by Spotify’s Daniel Ek, has raised a $700 million Series C, the company announced on July 15, 2026. It is one of the largest funding rounds in European health tech to date, and it comes as Neko prepares to launch in the United States.

The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from returning backers Atomico, General Catalyst, and Lakestar, and new investors Liberty City Ventures, Positive Sum, and BDT & MSD.

A Notable Cap Table

The raise also drew an unusually high-profile list of individual investors, including Mark Zuckerberg and Priscilla Chan, alongside names such as Tim Ferriss, Maria Sharapova, Thierry Henry, Jimmy Iovine, Gary Vaynerchuk, Alexis Ohanian, Claudia Schiffer, Danny Meyer, Steven Bartlett, Zoë Saldaña, and will.i.am.

The round brings Neko’s total funding to roughly $960 million, following the $260 million Series B it raised in January 2025 at a $1.8 billion valuation.

The Traction Behind the Round

Neko’s pitch is a roughly one-hour full-body scan designed to catch health issues early — a “proactive” alternative to reactive medicine. The company says the model is showing demand and results:

• More than 350,000 people are registered or on the waitlist;
• Over 100,000 scans have been completed across the UK and Sweden; and
• The company has described its clinics as profitable at the clinic level.

“The vast majority of our members return after their first scan, and when they do, their health markers move in the right direction,” said Hjalmar Nilsonne, Neko Health’s co-founder and CEO.

Neko currently operates clinics in Stockholm, London, Manchester, and Birmingham, and designs its hardware, software, and clinical protocols in-house.

The US Bet

The headline use of the capital is Neko’s first move into the United States, with clinics planned for New York in 2026 — the company’s largest and most competitive market yet.

“With this round, we’re taking that mission to the US for the first time, while continuing to invest in the research and technology that make prevention possible at scale,” said Nilsonne.

Why It Matters

The scale of the round is a signal in itself: preventive, consumer-paid health scanning has moved from a fringe idea to one of the most heavily funded bets in European health tech. Neko is arriving in the US just as the category heats up — from full-body MRI startups to newer entrants promising faster, cheaper scans — and the central questions travel with it: whether early, frequent scanning meaningfully improves long-term outcomes, whether it can be priced for more than an affluent early-adopter base, and whether “find more, earlier” avoids the overdiagnosis that has dogged broad screening. A $700 million round buys Neko a long runway to try to answer them at scale.

---

The round at a glance

• Company: Neko Health (Stockholm), co-founded by Daniel Ek and Hjalmar Nilsonne
• Round: $700 million Series C (total funding ~$960M)
• Lead investors: Lightspeed Venture Partners (lead), O.G. Venture Partners (co-lead)
• Also participating: Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, BDT & MSD, plus individuals including Mark Zuckerberg and Priscilla Chan
• Traction: 100,000+ scans completed; 350,000+ registered or waitlisted; profitable at clinic level
• Use of funds: US launch (New York, 2026); continued R&D

Details drawn from Neko Health’s announcement and press coverage (Sifted, BusinessCloud, TechFundingNews), July 2026. Membership, scan, and profitability figures are as reported by the company and have not been independently verified. The Series C valuation was not disclosed.